Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22770534 | 0.82 | ALDH1A1 (0.46) | CYP3A4CYP2C9ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL1963123 | 0.82 | HDAC1 (0.43) | CYP3A4CYP2C19CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL30801697 | 0.81 | HDAC1 (0.45) | CYP3A4ALDH1A1CYP1A2CYP2D6HPGD | |
| SCHEMBL5423537 | 0.80 | HDAC1 (0.44) | CYP3A4ALDH1A1CYP1A2CYP2D6HPGD | |
| SCHEMBL29967631 | 0.78 | ALDH1A1 (0.55) | CYP3A4ALDH1A1GAAL3MBTL1 | |
| SCHEMBL8294396 | 0.77 | MMP1 (0.47) | CYP3A4ALDH1A1GAAL3MBTL1 | |
| SCHEMBL18821256 | 0.77 | OPRM1 (0.45) | CYP3A4CYP2C19CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL12543528 | 0.77 | HDAC1 (0.51) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL17761442 | 0.76 | HDAC1 (0.54) | ALDH1A1GAAL3MBTL1 | |
| SCHEMBL2262766 | 0.75 | CYP3A4 (0.52) | CYP3A4ALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159800-A1 | MK2 INHIBITORS | N.V. ORGANON (NL) | 2016-06-09 | — | — | US | disclosed |
| US-9102676-B2 | MK2 inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2015-08-11 | — | — | US | disclosed |
| US-20140288109-A1 | MK2 INHIBITORS | N.V. ORGANON (NL) | 2014-09-25 | — | — | US | disclosed |
| US-8772286-B2 | MK2 inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2014-07-08 | — | — | US | disclosed |
| EP-2513111-B1 | MK2 INHIBITORS | MERCK SHARP & DOHME (NL) | 2013-10-02 | — | — | EP | disclosed |
| EP-2513111-A1 | MK2 INHIBITORS | MSD Oss B.V. (NL) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245175-A1 | MK2 INHIBITORS | N.V. ORGANON (NL) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073119-A1 | MK2 INHIBITORS | N.V. ORGANON (NL) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288109-A1 | MK2 INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | AADAT 1792/4885CYP3A4 4621/4885CYP2C19 3065/4885 |
| US-20160159800-A1 | MK2 INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | AADAT 1875/4885CYP3A4 4747/4885CYP2C19 3504/4885 |
| US-20120245175-A1 | MK2 INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | AADAT 1792/4885CYP3A4 4621/4885CYP2C19 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.